




**FULBRIGHT & JAWORSKI L.L.P.**

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER  
PARTNER  
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184  
TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

January 13, 2004

CERTIFICATE OF FACSIMILE TRANSMISSION 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being transmitted to: Commissioner for Patents, Washington, D.C. 20231, Attn: Examiner Richard Schnizer, GAU 1635, facsimile number (703) 703/872-5806 on the date below:	
January 13, 2004 Date	 Steven L. Highlander

Richard Schnizer, Examiner  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 09/448,613 entitled "METHODS AND COMPOSITIONS FOR INCREASING THE INFECTIVITY OF GENE TRANSFER VECTORS" – Paul McCray et al.*  
*Our reference: IOWA:022*

Dear Examiner Schnizer:

After reviewing each of the Office Actions and the Notice of Allowability, it has come to our attention that the Supplemental Information Disclosure Statement, Form PTO-1449 and 6 references submitted on March 7, 2002, were never signed off by an Examiner.

For your convenience we have enclosed a copy of a Supplemental Information Disclosure Statement, Form PTO-1449 and the transmittal letter that was filed with the Patent and Trademark Office (PTO) on March 7, 2002. Also enclosed is a copy of the PTO stamped postcard indicating the documents submitted to the PTO. The copies of the references have not been enclosed. Please let us know if we need to submit those as well.

25374527.1


HOUSTON • NEW YORK • WASHINGTON DC • AUSTIN • DALLAS • LOS ANGELES • MINNEAPOLIS • SAN ANTONIO • HONG KONG • LONDON • MUNICH

Commissioner for Patents  
January 13, 2004  
Page 2

Please review and approve this Supplemental Information Disclosure Statement. If you need additional information, please let us know.

Thank you for your assistance in this matter.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642

SLH/mar  
Encl: as noted

25374527.1

**FULBRIGHT & JAWORSKI L.L.P.**

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
800 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5301  
FACSIMILE: 512/536-4598

STEVEN L. HIGHLANDER  
PARTNER


INTERNET ADDRESS:  
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184

HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG

March 7, 2002

FILE: IOWA:022  
10008931

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
March 7, 2002 Date	 Steven L. Highlander

Commissioner for Patents  
Washington, DC 20231

RE: *SN 09/448,613 "METHODS AND COMPOSITIONS FOR INCREASING THE INFECTIVITY OF GENE TRANSFER VECTORS" - By Paul McCray et al.*

Commissioner:

Enclosed for filing in the above-referenced patent application is:


1. Amendment and Request for Reconsideration Under 37 C.F.R. §1.111 and Petition For Extension of Time;
2. A check for \$110.00 as the fee for the extension of time;
3. Supplemental Information Disclosure Statement; Form PTO-1449; References C100-C105;
4. A check for \$180.00 as the fee for the Supplemental Disclosure Statement; and
5. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

25142839.1

Commissioner for Patents  
March 7, 2002  
Page 2

If the check is inadvertently omitted, or the amount is insufficient, or should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, or should an overpayment be included herein, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski L.L.P. Account No.: 50-1212/10008931/SLH.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642

SLH/cpj  
Encl.:

25142839.1

Commissioner for Patents

March 7, 2002

Page 3

bcc: Bruce Wheaton, Ph.D. (w/encl.)  
Paul B. McCray, Jr., M.D. (w/encl.)  
Zev Sunleaf, Ph.D. (w/encl.)  
Anne Dollard, Esq. (w/encl.)

25142839.1

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTER

JAN 15 2004

In re Application of:  
Paul McCray *et al.*

Serial No.: 09/448,613

Filed: November 22, 1999

For: METHODS AND COMPOSITIONS FOR  
INCREASING THE INFECTIVITY OF  
GENE TRANSFER VECTORS

Group Art Unit: 1632

Examiner: Schnizer, Richard A.

Atty. Dkt. No.: IOWA:022/SLH

OFFICIAL

CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

March 6, 2002

Date

Steven L. Highlander

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTCommissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

25142197.1

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed herewith. If an appropriate check has not been enclosed, or if it is insufficient, the Commissioner is hereby authorized to deduct said fee from Fulbright & Jaworski Account No.: 50-1212/10008931/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

Date: March 6, 2002



Form PTO-1449 (modified)  List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Atty. Docket No. IOWA:022/SLH	Serial No. 09/448,613
	Applicant Paul McCray <i>et al.</i>	
	Filing Date: November 22, 1999	Group: 1632
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C100	Crystal, "Bad for cats, good for humans? Modified feline immunodeficiency virus for gene therapy," <i>J. Clinical Investigation</i> , 104(11):1491-1493, 1999.
	C101	Johnson <i>et al.</i> , "Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis," <i>Nature Genetics</i> , 2:21-25, 1992.
	C102	Lemarchand <i>et al.</i> , "In vivo adenovirus-mediated gene transfer to lungs via pulmonary artery," <i>J. Appl. Physiol.</i> , 76(6):2840-2845, 1994.
	C103	Wang <i>et al.</i> , "Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect," <i>J. Clinical Investigation</i> , 104:R55-R62, 1999.
	C104	Wang <i>et al.</i> , "Increasing epithelial junction permeability enhances gene transfer to airway epithelia In Vivo," <i>Am. J. Respir. Cell Mol. Biol.</i> , 22:129-138, 2000.
	C105	Zhou <i>et al.</i> , "Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR," <i>Science</i> , 266:1705-1708, 1994.

25142057.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Please indicate receipt of the below-identified paper:

<input type="checkbox"/> New Application For:		Priority Date:	
<input type="checkbox"/> Foreign priority already claimed			
<input type="checkbox"/> Continuation	<input type="checkbox"/> CIP	<input type="checkbox"/> Divisional	CPA <input type="checkbox"/>
<input type="checkbox"/> Specification:	Pages:	<input type="checkbox"/> Drawings:	Sheets
<input checked="" type="checkbox"/> Response to Office Action Dated: November 27, 2001		<input type="checkbox"/> Final Rejection	
<input checked="" type="checkbox"/> Other: TRAN. LTR.; AMEND. AND REQ. FOR RECON. UNDER 37 CFR 1.111 AND PET. FOR EXT. OF TIME/CAT. \$110.00 CHECK; SUPPL. IDS; FORM PTO-1449; REF. C100-C105; \$180.00 CHECK AND POSTCARD.			
<input type="checkbox"/> Assignment Enclosed	<input checked="" type="checkbox"/> Cert. of Timely Mailing	<input type="checkbox"/> Exp. Mail:	

### IDENTIFICATION OF APPLICATION

Serial No.: 09/448,613	
Title: METHODS AND COMPOSITIONS FOR INCREASING THE EFFECTIVITY OF GENE TRANSFER VECTORS	
Applicant: PAUL MCCRAY, JR. ET AL.	Attorney: SLH
Client: UNIV. OF IOWA RESEARCH FOUNDATION	F&J File No.: 09/448,613
Mailed:	Filed: 3/07/02 Due Date: 3/27/02



ATTN DOCKETING  
FULBRIGHT & JAWORSKI LLP  
600 CONGRESS AVE STE 2400  
AUSTIN TX 78701-9930

MAR 23 2002

NO POSTAGE  
NECESSARY  
IF MAILED  
IN THE  
UNITED STATES

